Drugs / KDR2-2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04844619 | Apr 2021 → Dec 2024 overdue | corneal neovascularization, neovascular glaucoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05011916 | Aug 2021 → Aug 2022 | corneal neovascularization | Zhongshan Ophthalmic Center, Sun Yat-sen University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04620109 Comparator | Aug 2020 → Mar 2021 | corneal neovascularization | Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KDR2-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05011916 ↗ |
| Action | Inhibit | “highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2)” NCT04620109 ↗ |
| Modality | Small molecule | “synthetic anti-angiogenic chemical compound” NCT04620109 ↗ |
| Route | Topical | “KDR2-2 or placebo will be topically administered in the right eye” NCT04620109 ↗ |